BICO Group

BICO Group AB (publ) is a global bio-convergence enterprise, operating in North America, Europe, Asia, and other international markets. The company focuses on advanced laboratory solutions and bioautomation, catering primarily to the medical, pharmaceutical, and cosmetic sectors.

Products and Services

• 3D bioprinters and hybrid microscopy systems
• Precision dispensing and biosensor technology for diagnostics
• 3D cell culture and tissue imaging services

Growth Outlook

• Revenue of 329.9 million SEK in Q1 2026, showing potential for recovery
• Gross profit margin improved to 54.1% in Q1 2026
• Strong cash position with 744.3 million SEK in cash and equivalents

Financial Highlights

• Net income of -131.3 million SEK in Q1 2026, reflecting ongoing challenges
• Operating income margin at -27.6% in Q1 2026, indicating operational adjustments
• Current ratio of 2.35, suggesting strong liquidity position

BICO Group AB (publ) has established itself as a leader in the bio-convergence sector, with a diverse range of products and services that cater to various industries. The recent quarterly results indicate a revenue of 329.9 million SEK, which reflects a potential for recovery after previous challenges. The gross profit margin has shown improvement, reaching 54.1% in Q1 2026, which is a positive sign for operational efficiency. Despite facing a net income loss of 131.3 million SEK in the same quarter, the company maintains a strong liquidity position with a current ratio of 2.35. This suggests that BICO Group is well-positioned to meet its short-term obligations. The cash reserves of 744.3 million SEK provide a buffer for future investments and operational needs. Overall, BICO Group AB (publ) presents a compelling opportunity for investors interested in the bio-convergence and medical device sectors, particularly as the company navigates its growth trajectory and operational adjustments.